Medical/Pharmaceuticals APAC News & Press Release Distribution

Medical/Pharmaceuticals

All
Global

CBC Group Completes Strategic Acquisition of UCB's Mature Product Portfolio in China

* CBC Group and Mubadala acquire UCB's mature neurology and allergy business inChina for US$680 million. * New company is named NeuroGen Pharma, led by an experienced management team with a strong track record in the biopharma industry. * Strategic acquisition under CBC's buyout strategy exp...

2024-11-30 09:00 8266

"Are your Hands & Feet trying to tell you something?" - Ask leading Health Experts

* Do you feel numbness, pain, tingling or pins and needles in your hands and feet? * 8 out of 10 patients with Peripheral Neuropathy don't listen to what their nerves are telling them and go undiagnosed leading to worsening of symptoms. MANILA, Philippines, Nov. 29, 2024 /PRNewswire/ -- As pa...

2024-11-29 13:30 3231

Borsch Med Partners with Unity Pharmacies to Help Elderly Access Zeria Chondroitin-based Joint Health Supplements in Support of Healthy Ageing in Singapore

SINGAPORE, Nov. 29, 2024 /PRNewswire/ -- Leading health and nutrition company, Borsch Med Pte Ltd (Borch Med) has announced that Zeria chrondroitin-based joint health supplements are now available at selected Unity pharmacies in Singapore. The enhanced distribution network of the Japanese-made sup...

2024-11-29 10:00 2950

Borsch Med Partners with Unity Pharmacies to Help Elderly Access Zeria Chondroitin-based Joint Health Supplements in Support of Healthy Ageing in Singapore

Microbio Appoints Paul Brennan as Chair of the Board

BRISBANE, Australia, Nov. 29, 2024 /PRNewswire/ -- Microbio Ltd, the Australian pathogen diagnostics company specialising in innovative molecular diagnostic solutions, has appointedPaul Brennan as Chair of the Board, effective 2nd December 2024. Paul brings extensive global experience as a Non-E...

2024-11-29 06:30 3571

Lanchi Ventures Leads $42M Series A Financing for Allink Biotherapeutics to Accelerate Global Development of Bispecific Antibody and ADC Pipeline

The series A investment round secures resources for advancing global Phase I/II clinical programs and orchestrating the company's global footprint expansion. BEIJING, Nov. 28, 2024 /PRNewswire/ -- Allink Biotherapeutics, a clinical-stage biotechnology company pioneering next-generation bispecific...

2024-11-28 21:30 5387

First Patient Dosed in Phase III ZIRCON-CP Trial of TLX250-CDx for Kidney Cancer Imaging in Chinese Patients

MELBOURNE, Australia, Nov. 28, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX; Nasdaq: TLX, Telix, the Company) and Grand Pharmaceutical Group Limited (00512.HK, Grand Pharma) today announce that a first patient has been dosed in the Phase III ZIRCON-CP trial of TLX250-CDx positron ...

2024-11-28 17:22 3738

New Indication of Olverembatinib Included into China 2024 National Reimbursement Drug List

ROCKVILLE, Md. and SUZHOU, China, Nov. 28, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global unmet medical needs primarily for malignancies, today announced that the new indication...

2024-11-28 16:59 4781

Own Your Story with AwarerHOME™

Malaysia's HIV Oral Self-Test for Accessible and Confident Testing KUALA LUMPUR, Malaysia, Nov. 28, 2024 /PRNewswire/ -- Say hello to confidence and control with AwarerHOME™,Malaysia's first homegrown HIV Oral Self-Test. This accessible, no-mess, no-fuss solution offers something even more impor...

2024-11-28 16:34 3345

Everest Medicines Announces NEFECON®, the World's First Approved Treatment for IgA Nephropathy, is Included in China's National Reimbursement Drug List

SHANGHAI, Nov. 28, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that NEFECON® has been included in the...

2024-11-28 13:43 3393

Antengene Announces XPOVIO®'s New Indication Included in 2024 China National Reimbursement Drug List, Making the Drug More Accessible to DLBCL Patients in the Country

SHANGHAI and HONG KONG, Nov. 28, 2024 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for hema...

2024-11-28 13:04 4152

Innovent Announces First-Time Inclusion of SINTBILO® and New Indication for Olverembatinib in China's National Reimbursement Drug List

SAN FRANCISCO and SUZHOU, China, Nov. 28, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune...

2024-11-28 12:07 5616

Newbase Launches 'Medicrew', a VR Medical Training Platform to Accelerate Global Market Expansion

Participation in IMSH 2025 to Showcase Innovations in Medical Education SEOUL, South Korea, Nov. 28, 2024 /PRNewswire/ -- Newbase , a leader in metaverse-based medical education platforms, announced on the 28th the launch of its new product, 'Medicrew', a platform des...

2024-11-28 09:00 3542

Newbase Launches 'Medicrew', a VR Medical Training Platform to Accelerate Global Market Expansion

Prenetics Announces Third Quarter 2024 Financial Results

Revenue Grew 59.4% to $7.8 million from Prior Year and 30.9% Sequentially Officially Launched IM8Health.com, a new premium supplements brand Tencent Invests $30 million in Insighta's Early Cancer Detection Reiterates Revenue Target to Exceed $33 million for FY 2024 CHARLOTTE, N.C., Nov. 27, 2024 /P...

2024-11-27 21:30 4683

Everest Medicines to Hold Investor Calls on Data Results from EVER001 Phase 1b/2a Clinical Study in Primary Membranous Nephropathy

SHANGHAI, Nov. 27, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that it will hold investor calls on t...

2024-11-27 19:08 4309

Kelun-Biotech's TROP2 ADC Sacituzumab tirumotecan (sac-TMT) Approved For Marketing By NMPA Of China For 2L+ Advanced or Metastatic TNBC

CHENGDU, China, Nov. 27, 2024 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that the Company received marketing authorization inChina from National Medical Products Administration (NMPA) for the first domestically developed trophoblast cell-surface an...

2024-11-27 14:34 3358

8 in 10 say a healthier diet is important to support mental and physical health - Herbalife Asia Pacific survey

HONG KONG, Nov. 27, 2024 /PRNewswire/ -- Herbalife, a premier health and wellness company and community, today released findings from itsAsia Pacific "New Year, New Me" survey,which revealed that 85% of consumers say a healthier diet is important to support their mental and physical health. Almos...

2024-11-27 11:00 3040

IMG Releases 2024 Holiday Travel Trends

* IMG has reviewed a sample of member data including more than 17,000 travel itineraries of travelers with upcoming travel plans between Thanksgiving Day and New Year's Day to determine emerging travel trends this holiday season. INDIANAPOLIS, Nov. 26, 2024 /PRNewswire/ -- IMG (International Me...

2024-11-26 22:00 2485

QDX Co-Founder Giuseppe Barca Awarded Prestigious Gordon Bell Prize, Pioneering Advancements in Drug Discovery Technology

SINGAPORE, Nov. 26, 2024 /PRNewswire/ -- QDX proudly announces that the team led by its co-founder, Associate ProfessorGiuseppe Barca, has been honoured with the 2024 ACM Gordon Bell Prize, often referred to as the "Nobel Prize of high-performance computing." This accolade recognizes their ground...

2024-11-26 18:49 9782

Menarini Group Presents New and Expanded Data at the 2024 San Antonio Breast Cancer Symposium Reinforcing the Role of ORSERDU® (Elacestrant) for Patients with ER+, HER2- Advanced or Metastatic Breast Cancer (mBC)

* Real-world evidence bolsters the efficacy of ORSERDU for the treatment of patients with ER+/HER2- ESR1-mut advanced or mBC. * Updated results of elacestrant in combination with abemaciclib show favorable efficacy regardless of theESR1 mutation status, with a manageable and predictable safet...

2024-11-26 17:16 4157

Hong Kong: A Hub of Innovation Leading the Future of AI in Healthcare，The 2nd CREATE Symposium Hosted by CAIR Concludes Successfully

HONG KONG, Nov. 26, 2024 /PRNewswire/ -- In recent years, the integration of artificial intelligence (AI) and robotics into the medical field has revolutionized healthcare technologies. The focus now is on bridging the gap between cutting-edge technologies and clinical applications to enhance di...

2024-11-26 12:08 4054

1 ... 132 133 134135136 137 138 ... 381